Shawn Layden says rising AAA costs cut game variety, risking “triple digit millions” losses
The former PlayStation America president argues higher budgets drive risk tolerance to zero, squeezing quirky “unicorn” ideas out.

Shawn Layden, former president of Sony Interactive Entertainment America, says modern games look too similar because the rising cost of development forces publishers to demand safer bets. For decision-makers, the consequence is simple: when budgets get massive, funding and pitching behavior shift toward sequels and familiar formulas.
Shawn Layden, the former president of Sony Interactive Entertainment America, warns that the industry has “lost a lot of the variety in games,” and he directly ties the problem to one economic reality: rising costs make risk feel unaffordable. In his view, when new AAA projects can land in “triple digit millions” territory, studios stop chasing weird, distinct concepts. His bottom line is blunt: “if every throw of the dice is triple digit millions, then risk tolerance goes to about zero.”
Layden’s argument has a very specific picture behind it. He recalls being “at a game awards show a couple of years ago” and feeling disappointed because the games he saw largely clustered into the same themes: “zombie apocalypse,” “some kind of space marines,” or “guys in medieval Europe with really big swords.” He says that kind of sameness becomes the default when “there's so many games that looked like the game next to it.” And he raises the alarm about what that means for players who want novelty, explicitly worrying that quirky staples like “PaRappa the Rapper” no longer get made.
Why does this happen? Because budgets change decision-making. Layden points to reports earlier this year that new AAA games can cost upwards of $300 million to make, and he uses that math to explain shifting publisher behavior. If development costs explode, the industry naturally raises its bar for what counts as success, which then narrows the set of projects executives are willing to fund. In other words, the problem is not that innovation disappears overnight. It is that the process for approving risk becomes much harder when a “maybe it works” project can cost what used to be a small slate of games.
He draws a contrast to the PlayStation One era, where he says production economics made experimentation feasible. Layden notes that back on PS1, studios could back games “for $5 or $6 million,” and that changed how many shots developers could take: “then you'd do ten games.” The key detail is what he describes as manageable downside. He says you could “literally throw away $6 to $7 million on a project that didn't work,” and still treat the failure as learning. The second-order effect matters for boards and investors because learning is a form of capital efficiency. Small losses enable iterative discovery, and iterative discovery is where original genres and unlikely hits come from.
But with modern budgets, Layden argues that learning becomes expensive. “Now, if every throw of the dice is triple digit millions, then risk tolerance goes to about zero,” he says. That changes what dev teams pitch and what executives expect to hear. Layden describes the types of questions that can greet proposals, including whether a project is “a sequel” or tied to “established IP.” He also imagines the compressed creative pitch language studios face, like framing an idea as “like Fortnite meets Call of Duty in Zombieland.” The point is not that those comparisons never make sense. It is that the comparison becomes a gate, not a tool.
Layden then makes the “unicorn” problem explicit. He says “no one wants to take a risk on unicorn ballet in space.” Even if the idea is “really super exciting,” he argues, financing tends not to show up for it. And he extends that logic to how success metrics shape strategy: he argues that if games are judged “solely on revenue projections,” then risk tolerance stays near zero. For executives, this is a governance issue as much as a creative one. When boards and leadership teams optimize for predictable revenue models, the organization learns to suppress outliers, even if those outliers are what build long-term audience expansion.
Importantly, Layden does not claim that non-mainstream games no longer exist. His claim is about frequency and access to the production pipeline. He points to examples of differentiation that succeeded: Clair Obscur: Expedition 33’s popularity last year, which he suggests was driven at least in part by its blend of action and turn-based combat, “delightfully French vibes,” and a “stellar story.” He also references Balatro before it blew up, emphasizing that a “Poker-themed roguelike deckbuilder full of illegal cards and weird Jokers” is the kind of mix that is hard to predict and hard to categorize into a familiar template. His conclusion is a plea for supply: “let's have more unique, weird, and wonderful games, please.”
The strategic stakes are broader than any single publisher. If rising costs push the market toward “shooter, shooter, shooter,” then audiences get fewer genre surprises, and customer acquisition may slow because fewer people find games that feel made for them. Layden even warns about “the opportunity to attract new users,” suggesting that limiting variety reduces the chance to broaden the player base. For any executive or investor tracking interactive entertainment, the question becomes: how does your organization still fund discovery when the financial unit of risk keeps inflating?
This story's Key Insights and Take-aways are locked.
Create a free account to unlock Executive Actions for one credit.
Register to UnlockAlways free for Executives Club members. Join the Club
More in Business

SK Hynix opens at $170, raises $26.5B, and tops foreign IPO records
In Friday's Wall Street debut, SK Hynix turns AI RAM demand into a $26.5B fundraising moment that rewrites comps.

China lands a reusable Long March booster, a first that matches SpaceX and Blue Origin
A barge landing and net-based recovery move China from theory to proof, reshaping the reusability race and satellite ambitions.
AstraZeneca $27B wipeout as Wainua late trial misses cardiovascular target
A failed late-stage heart study triggered a swift market punishment, forcing investors and boards to reset timelines and risk.

